Strategic Blueprint’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Strategic Blueprint's BMY Position: Q3 2026 in Review
Strategic Blueprint reduced its Bristol-Myers Squibb (BMY) stake by 4.4% in Q3 2026, selling an estimated $15.6K and leaving 5,325 shares worth $332K. The position accounts for 0.02% of the portfolio, ranked #543.
Strategic Blueprint first reported a position in BMY in Q3 2019 and has held it in 23 quarters since. The position peaked at $938K in Q1 2024. 2,570 funds tracked by Wall St. Rank hold BMY as of Q3 2026.
- Strategic Blueprint held 5,325 shares of Bristol-Myers Squibb worth $332K as of Q3 2026.
- Strategic Blueprint sold 247 Bristol-Myers Squibb shares in Q3 2026, an estimated $15.6K.
- Bristol-Myers Squibb made up 0.02% of Strategic Blueprint's portfolio in Q3 2026, its #543 holding.
- Strategic Blueprint first reported a position in Bristol-Myers Squibb in Q3 2019 and has held it in 23 quarters since.
- Strategic Blueprint's Bristol-Myers Squibb position peaked at $938K in Q1 2024.
- 2,570 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.
Based on Strategic Blueprint's 13F filing for Q3 2026, filed 22 Oct 2026.